MYGN EBITDA | MYRIAD GENETICS, INC.

MYRIAD GENETICS, INC. (MYGN) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$38.90M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$30.70M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$23.30M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$329.20M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2009-06-30 to 2013-06-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$38.90M	(m)	$190.70M	(m)	(m)	-$8.30M*	$63.70M	$25.00M	(m)	$600.00K
2026-03-31	Reported	(m)	-$30.70M	(m)	$200.40M	(m)	(m)	-$15.70M	$62.80M	$27.10M	(m)	$0.00
2025-09-30	Reported	(m)	-$23.30M	(m)	$205.70M	(m)	(m)	$21.10M*	$61.90M	$28.20M	(m)	$1.20M
2025-06-30	Reported	(m)	-$329.20M	(m)	$213.10M	(m)	(m)	-$13.60M*	$61.30M	$25.60M	(m)	-$100.00K
2025-03-31	Reported	(m)	-$29.00M	(m)	$195.90M	(m)	(m)	-$16.30M	$61.70M	$27.50M	(m)	-$29.30M
2024-09-30	Reported	(m)	-$20.00M	(m)	$213.30M	(m)	(m)	$700.00K*	$63.50M	$28.50M	$139.10M	$900.00K
2024-06-30	Reported	(m)	-$36.50M	(m)	$211.50M	(m)	(m)	$2.60M*	$64.40M	$27.10M	$144.90M	-$500.00K
2024-03-31	Reported	(m)	-$27.90M	(m)	$202.20M	(m)	(m)	-$18.60M	$64.60M	$24.90M	$140.60M	$100.00K
2023-09-30	Reported	(m)	-$60.10M	(m)	$191.90M	(m)	(m)	-$22.10M*	$57.60M	$24.00M	$136.10M	$100.00K
2023-06-30	Reported	(m)	-$113.70M	(m)	$183.50M	(m)	(m)	-$900.00K*	$57.80M	$21.20M	$140.70M	$0.00
2023-03-31	Reported	(m)	-$52.20M	(m)	$181.20M	(m)	(m)	-$33.20M	$59.20M	$22.50M	$151.70M	$2.10M
2022-09-30	Reported	(m)	-$45.00M	(m)	$156.40M	(m)	(m)	-$2.80M*	$50.40M	$20.50M	$130.50M	-$9.10M
2022-06-30	Reported	(m)	-$17.80M	(m)	$179.30M	(m)	(m)	-$49.70M*	$49.70M	$20.30M	$127.10M	-$3.80M
2022-03-31	Reported	(m)	-$25.60M	(m)	$164.90M	(m)	(m)	-$46.50M	$48.00M	$21.20M	$110.60M	-$5.90M
2021-09-30	Reported	(m)	-$79.90M	(m)	$167.30M	(m)	(m)	-$39.30M*	(m)	$18.80M	$180.60M	$15.20M
2021-06-30	Reported	(m)	-$20.80M	(m)	$189.40M	(m)	(m)	-$4.40M*	(m)	$19.50M	$135.20M	$900.00K
2021-03-31	Reported	(m)	-$46.70M	(m)	$173.10M	(m)	(m)	$71.80M	(m)	$23.10M	$146.40M	-$10.10M
2020-12-31	Reported	(m)	-$48.20M	(m)	$154.60M	(m)	(m)	-$14.40M*	(m)	$18.20M	$132.80M	-$12.50M
2020-09-30	Reported	(m)	-$39.60M	(m)	$145.20M	(m)	(m)	-$59.30M	(m)	$17.60M	$124.10M	-$28.50M
2020-06-30	Reported	(m)	-$68.30M	(m)	$93.20M	(m)	(m)	$30.00M*	(m)	$17.40M	$107.40M	-$3.00M
2020-03-31	Reported	(m)	-$133.70M	(m)	$164.00M	(m)	(m)	$16.80M	(m)	$19.70M	$132.90M	-$15.90M
2019-12-31	Reported	(m)	-$8.80M	(m)	$195.10M	(m)	(m)	-$1.90M*	(m)	$18.80M	$134.30M	-$3.10M
2019-09-30	Reported	(m)	-$20.90M	(m)	$186.30M	(m)	(m)	$15.80M	(m)	$21.30M	$135.50M	-$1.70M
2019-06-30	Reported	(m)	-$5.60M	(m)	$215.40M	(m)	(m)	(m)	(m)	$20.90M	$149.80M	-$3.40M
2019-03-31	Reported	(m)	$5.90M	(m)	$216.60M	(m)	(m)	$6.60M*	(m)	$21.50M	$140.60M	-$3.60M
2018-12-31	Reported	(m)	$6.10M	(m)	$216.80M	(m)	(m)	$37.80M*	(m)	$22.40M	$135.20M	$1.00M
2018-09-30	Reported	(m)	$1.20M	(m)	$202.30M	(m)	(m)	$7.80M	(m)	$21.10M	$129.90M	$1.60M
2018-06-30	Reported	(m)	$17.80M	(m)	$193.90M	(m)	(m)	(m)	(m)	$17.70M	$112.50M	$3.50M
2018-03-31	Reported	(m)	$13.80M	(m)	$183.10M	(m)	(m)	$11.50M*	(m)	$18.50M	$107.90M	$4.30M
2017-12-31	Reported	(m)	$6.30M	(m)	$187.90M	(m)	(m)	$33.00M*	(m)	$16.80M	$107.40M	-$25.30M
2017-09-30	Reported	(m)	$84.00M	(m)	$178.80M	(m)	(m)	$23.50M	(m)	$17.80M	$107.20M	$4.50M
2017-06-30	Reported	(m)	$18.90M	(m)	$199.60M	(m)	(m)	(m)	(m)	$18.80M	$122.10M	$5.80M
2017-03-31	Reported	(m)	$5.50M	(m)	$194.70M	(m)	(m)	(m)	(m)	$17.60M	$122.10M	$3.00M
2016-12-31	Reported	(m)	$17.20M	(m)	$196.70M	(m)	(m)	(m)	(m)	$18.60M	$120.30M	$6.20M
2016-09-30	Reported	(m)	$7.10M	(m)	$178.90M	(m)	(m)	(m)	(m)	$19.40M	$111.90M	$5.60M
2016-03-31	Reported	(m)	$42.60M	(m)	(m)	(m)	(m)	(m)	(m)	$17.20M	$90.50M	$8.60M
2015-12-31	Reported	(m)	$45.20M	(m)	(m)	(m)	(m)	(m)	(m)	$16.70M	$90.80M	$7.90M
2015-09-30	Reported	(m)	$43.30M	(m)	(m)	(m)	(m)	(m)	(m)	$17.20M	$86.50M	$13.20M
2015-03-31	Reported	(m)	$35.70M	(m)	(m)	(m)	(m)	(m)	(m)	$16.70M	$91.30M	$14.10M
2014-12-31	Reported	(m)	$36.30M	(m)	(m)	(m)	(m)	(m)	(m)	$17.50M	$92.70M	$13.90M
2014-09-30	Reported	(m)	$25.90M	(m)	(m)	(m)	(m)	(m)	(m)	$22.60M	$85.40M	$9.90M
2014-03-31	Reported	(m)	$55.29M	(m)	(m)	(m)	(m)	$11.25M*	(m)	$13.40M	$87.63M	$20.57M
2013-12-31	Reported	(m)	$83.00M	(m)	(m)	(m)	(m)	$47.55M*	(m)	$17.09M	$77.84M	$33.78M
2013-09-30	Reported	(m)	$82.90M	(m)	(m)	(m)	(m)	$90.48M	(m)	$16.80M	$77.28M	$28.36M
2013-06-30	Reported	$68.17M	(m)	(m)	(m)	39.14%	(m)	(m)	(m)	(m)	(m)	(m)
2013-03-31	Reported	$60.10M*	$57.92M	$2.18M*	(m)	(m)	(m)	$37.40M*	(m)	$13.62M	$64.60M	$21.35M
2012-12-31	Reported	$57.83M*	$55.59M	$2.24M*	(m)	(m)	(m)	$22.11M*	(m)	$14.11M	$59.56M	$21.95M
2012-09-30	Reported	$50.79M	(m)	(m)	(m)	38.07%	(m)	$51.36M	(m)	$11.40M	$56.13M	$19.69M
2012-06-30	Reported	$49.61M	(m)	(m)	(m)	37.31%	(m)	(m)	(m)	(m)	(m)	(m)
2012-03-31	Reported	$48.40M*	$46.10M	$2.30M*	(m)	(m)	(m)	$40.75M*	(m)	$11.75M	$54.70M	$17.87M
2011-12-31	Reported	$47.76M*	$45.47M	$2.29M*	(m)	(m)	(m)	$27.53M*	(m)	$10.24M	$50.99M	$18.49M
2011-09-30	Reported	$43.62M	(m)	(m)	(m)	39.49%	(m)	$31.82M	(m)	$8.51M	$46.11M	$16.71M
2011-06-30	Reported	$43.66M	(m)	(m)	(m)	40.64%	(m)	(m)	(m)	(m)	(m)	(m)
2011-03-31	Reported	$43.62M*	$41.82M	$1.80M*	(m)	(m)	(m)	$28.04M*	(m)	$6.67M	$42.75M	$14.37M
2010-12-31	Reported	$40.37M*	$38.59M	$1.78M*	(m)	(m)	(m)	$37.13M*	(m)	$6.09M	$43.72M	$14.86M
2010-09-30	Reported	$37.35M	(m)	(m)	(m)	40.66%	(m)	$29.30M	(m)	$5.76M	$39.49M	$13.64M
2010-06-30	Reported	$39.41M	(m)	(m)	(m)	41.95%	(m)	(m)	(m)	(m)	(m)	(m)
2010-03-31	Reported	$35.00M*	$33.23M	$1.78M*	(m)	(m)	(m)	$42.66M*	(m)	$5.88M	$40.84M	$1.23M
2009-12-31	Reported	$36.26M*	$34.52M	$1.74M*	(m)	(m)	(m)	$42.73M*	(m)	$5.06M	$42.10M	$980.00K
2009-09-30	Reported	$31.49M	(m)	(m)	(m)	37.00%	(m)	$23.18M	(m)	$5.68M	$38.67M	$968.00K

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$387.20M	(m)	$824.50M	(m)	(m)	$1.80M	$247.90M	$106.80M	(m)	-$29.20M
2024-12-31	Reported	(m)	-$123.50M	(m)	$837.60M	(m)	(m)	-$8.70M	$252.20M	$113.40M	(m)	$3.80M
2023-12-31	Reported	(m)	-$257.40M	(m)	$753.20M	(m)	(m)	-$110.90M	$236.20M	$88.70M	$572.90M	$1.10M
2022-12-31	Reported	(m)	-$140.60M	(m)	$678.40M	(m)	(m)	-$106.30M	$202.00M	$85.40M	$514.70M	-$28.60M
2021-12-31	Reported	(m)	-$190.50M	(m)	$690.60M	(m)	(m)	$18.60M	(m)	$81.90M	$537.80M	-$29.90M
2021-09-30	Rolling	(m)	-$195.60M*	(m)	$684.40M*	(m)	(m)	$13.70M*	(m)	$79.60M*	$595.00M*	-$6.50M*
2021-06-30	Rolling	(m)	-$155.30M*	(m)	$662.30M*	(m)	(m)	-$6.30M*	(m)	$78.40M*	$538.50M*	-$50.20M*
2021-03-31	Rolling	(m)	-$202.80M*	(m)	$566.10M*	(m)	(m)	$28.10M*	(m)	$76.30M*	$510.70M*	-$54.10M*
2020-12-31	Reported	(m)	-$289.70M	(m)	$557.10M	(m)	(m)	(m)	(m)	$73.30M	$496.90M	-$59.90M
2020-12-31	Rolling	(m)	-$289.80M*	(m)	$557.00M*	(m)	(m)	-$26.90M*	(m)	$72.90M*	$497.20M*	-$59.90M*
2020-09-30	Rolling	(m)	-$250.40M*	(m)	$597.50M*	(m)	(m)	-$14.40M*	(m)	$73.50M*	$498.70M*	-$50.50M*
2020-06-30	Reported	(m)	-$231.70M	(m)	$638.60M	(m)	(m)	$60.70M	(m)	$77.20M	$507.30M	-$23.70M
2020-06-30	Rolling	(m)	-$231.70M*	(m)	$638.60M*	(m)	(m)	$60.70M*	(m)	$77.20M*	$510.10M*	-$23.70M*
2020-03-31	Rolling	(m)	-$169.00M*	(m)	$760.80M*	(m)	(m)	(m)	(m)	$80.70M*	$552.50M*	-$24.10M*
2019-12-31	Rolling	(m)	-$29.40M*	(m)	$813.40M*	(m)	(m)	(m)	(m)	$82.50M*	$560.20M*	-$11.80M*
2019-09-30	Rolling	(m)	-$14.50M*	(m)	$835.10M*	(m)	(m)	(m)	(m)	$86.10M*	$561.10M*	-$7.70M*
2019-06-30	Reported	(m)	$7.60M	(m)	$851.10M	(m)	(m)	$83.70M	(m)	$85.90M	$556.60M	-$4.40M
2019-06-30	Rolling	(m)	$7.60M*	(m)	$851.10M*	(m)	(m)	(m)	(m)	$85.90M*	$555.50M*	-$4.40M*
2019-03-31	Rolling	(m)	$31.00M*	(m)	$829.60M*	(m)	(m)	(m)	(m)	$82.70M*	$518.20M*	$2.50M*
2018-12-31	Rolling	(m)	$38.90M*	(m)	$796.10M*	(m)	(m)	(m)	(m)	$79.70M*	$485.50M*	$10.40M*
2018-09-30	Rolling	(m)	$39.10M*	(m)	$767.20M*	(m)	(m)	(m)	(m)	$74.10M*	$457.70M*	-$15.90M*
2018-06-30	Reported	(m)	$121.90M	(m)	$743.70M	(m)	(m)	$115.90M	(m)	$70.80M	$435.00M	-$13.00M
2018-06-30	Rolling	(m)	$121.90M*	(m)	$743.70M*	(m)	(m)	(m)	(m)	$70.80M*	$435.00M*	-$13.00M*
2018-03-31	Rolling	(m)	$123.00M*	(m)	$749.40M*	(m)	(m)	(m)	(m)	$71.90M*	$444.60M*	-$10.70M*
2017-12-31	Rolling	(m)	$114.70M*	(m)	$761.00M*	(m)	(m)	(m)	(m)	$71.00M*	$458.80M*	-$12.00M*
2017-09-30	Rolling	(m)	$125.60M*	(m)	$769.80M*	(m)	(m)	(m)	(m)	$72.80M*	$471.70M*	$19.50M*
2017-06-30	Reported	(m)	$44.00M	(m)	$728.70M	(m)	(m)	$106.20M	(m)	$74.40M	$439.90M	$19.00M
2017-06-30	Rolling	(m)	$48.70M*	(m)	$769.90M*	(m)	(m)	(m)	(m)	$74.40M*	$476.40M*	$20.60M*
2016-06-30	Reported	(m)	$153.40M	(m)	$740.50M	(m)	(m)	$166.30M	(m)	$70.60M	$359.20M	$38.80M
2015-06-30	Reported	(m)	$133.60M	(m)	$722.50M	(m)	(m)	(m)	(m)	$75.50M	$366.00M	$54.50M
2014-06-30	Reported	(m)	$274.40M	(m)	(m)	(m)	(m)	(m)	(m)	$67.50M	$327.10M	$101.60M
2013-06-30	Reported	$236.89M	(m)	(m)	(m)	38.63%	(m)	$173.87M	(m)	$53.70M	$251.80M	$86.10M
2012-06-30	Reported	$189.39M	(m)	(m)	(m)	38.18%	(m)	$141.80M	(m)	$42.65M	$208.38M	$72.39M
2011-06-30	Reported	$165M	(m)	(m)	(m)	41.04%	(m)	$130.83M	(m)	$27.75M	$169.84M	$58.94M
2010-06-30	Reported	$142.16M	(m)	(m)	(m)	39.20%	(m)	$155.09M	(m)	$21.87M	$161.41M	-$11.47M
2009-06-30	Reported	$135.91M	(m)	(m)	(m)	41.62%	(m)	$84.04M	(m)	$17.91M	$138.88M	$193.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Alpha Teknova, Inc. (TKNO)	United States	$0.500B	-18.12
Insight Molecular Diagnostics Inc. (IMDX)	United States	$0.129B	-3.90
IMMUCELL CORP /DE/ (ICCC)	United States	$0.091B	116.10
QuidelOrtho Corp (QDEL)	United States	$0.733B	-0.90
BIOMERICA INC (BMRA)	United States	$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)	United States	$0.008B	-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)	United States	$0.006B
VOLITIONRX LTD (VNRX)		$0.003B	-0.64
ACHIEVE LIFE SCIENCES, INC. (ACHV)	United States	$0.806B	-5.88
Intellia Therapeutics, Inc. (NTLA)	United States	$1.705B	-5.92